TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

34 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

28 studies on the map

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease — Stanford University Medical Center, StanfordA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH — GSK Investigational Site, ArcadiaA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH — GSK Investigational Site, ArcadiaA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH — Akero Clinical Study Site, BirminghamMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH — 89bio Clinical Study Site, BirminghamLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — The Institute for Liver Health II DBA Arizona Clinical Trials, PeoriaFibrosis Lessens After Metabolic Surgery — Banner Health Center, PhoenixSAD Study in Patients With Parkinson's Disease and Motor Fluctuations — Rocky Mountain Clinical Research, EnglewoodProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraA Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment — Alloy Clinical Research LLC, KissimmeeOpen-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD — Digestive & Liver Center of Florida, OrlandoGlycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes — University Health - Texas Diabetic Institute, San AntonioA Self-Guided Mobile Intervention for Adults With Binge Eating and Obesity — Drexel University, PhiladelphiaDiazoxide Suppression Test P&F Study — Columbia University Irving Medical Center, New YorkEffect of Tirzepatide on Markers of MASLD in Patients With Obesity — University of New Mexico Health Sciences Center, AlbuquerqueHuman Models of Selective Insulin Resistance: Alpelisib, Part I — Columbia University Irving Medical Center, New YorkGraded Insulin Suppression Test P&F — Columbia University Irving Medical Center, New YorkOptimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease — Cleveland Clinic Main Campus, ClevelandEffect of Insulin Lowering on Lipogenesis — Columbia University Irving Medical Center, New YorkPrevention of Progression of Prediabetes, Obesity and CV Risk — University of Texas Health Science Center at San Antonio, San AntonioIndividualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder — Mayo Clinic, RochesterMechanism of SGLT2 Inhibition in the Kidney — University of Michigan, Ann ArborEvaluating the Pharmacokinetics and Safety of Miricorilant — Site# 433, San AntonioEvaluation of Miricorilant on Liver Fat in Patients With MASLD — University of Missouri, ColumbiaFeasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD — University of Tennessee Medical Center, KnoxvilleEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, Bethesda